Docetaxel

Generic Name: Docetaxel

Brand Names: Taxotere, Docetaxel Accord, Docetaxel Kabi

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₃NO_₁₄

CAS Number: 114977-28-5

Unique Ingredient Identifier: 699121PHCA

Background: Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...

Indication: Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer

Associated Therapies: -

Clinical Trials

Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2003-11-21

Last Posted Date: 2005-08-30

Lead Sponsor: Titan Pharmaceuticals

Target Recruit Count: 225

Registration Number: NCT00073385

Locations: 🇮🇳
Regional Cancer Centre, Thiruvananthapuram, India
🇺🇸
Hematology and Oncology Specialists, LLC, New Orleans, Louisiana, United States
🇬🇧
University of Edinburgh, Edinburgh Cancer Centre, Edinburgh, United Kingdom

and more 5 locations

Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer
Thromboembolism

First Posted Date: 2003-11-13

Last Posted Date: 2013-01-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00014352

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Celecoxib
Drug: Docetaxel

First Posted Date: 2003-10-21

Last Posted Date: 2013-04-29

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 24

Registration Number: NCT00030420

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2003-10-15

Last Posted Date: 2018-08-13

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 25

Registration Number: NCT00015886

Locations: 🇺🇸
Cancer Centers of the Carolinas, Greenville, South Carolina, United States
🇺🇸
East Carolina University School of Medicine, Greenville, North Carolina, United States
🇺🇸
Palmetto Hematology/Oncology Associates, Spartanburg, South Carolina, United States

and more 3 locations

Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: Filgrastim
Drug: Docetaxel
Drug: Doxorubicin
Procedure: Surgery

First Posted Date: 2003-10-08

Last Posted Date: 2012-09-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 45

Registration Number: NCT00005800

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

Phase 1

Completed

Conditions: Male Breast Carcinoma
Stage IIIA Breast Cancer
Adult Solid Neoplasm
Inflammatory Breast Carcinoma
Stage IIIB Breast Cancer

Interventions: Drug: Capecitabine
Drug: Docetaxel
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Tipifarnib

First Posted Date: 2003-10-07

Last Posted Date: 2015-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT00070252

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
University of Wisconsin Medical School, Milwaukee, Wisconsin, United States

and more 4 locations

A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following Prostatectomy

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-10-06

Last Posted Date: 2011-06-08

Lead Sponsor: Sanofi

Target Recruit Count: 83

Registration Number: NCT00069888

Locations: 🇺🇸
Sanofi-Aventis US, Bridgewater, New Jersey, United States

MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-10-01

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 30

Registration Number: NCT00004886

Locations: 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷
Institut Curie - Section Medicale, Paris, France
🇩🇪
Haemato-Onkologische Praxis und Tagesklinik, Munich (Muenchen), Germany

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

Phase 2

Completed

Conditions: Lung Neoplasms
Ovarian Neoplasms
Cervix Neoplasms
Renal Neoplasms

Interventions: Drug: docetaxel
Drug: tariquidar
Other: 99mTc-sestamibi imaging

First Posted Date: 2003-09-16

Last Posted Date: 2012-10-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00069160

Locations: 🇺🇸
National Institutes of Health, Bethesda, Maryland, United States

Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: carboplatin
Drug: docetaxel

First Posted Date: 2003-09-11

Last Posted Date: 2020-09-09

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 74

Registration Number: NCT00068341

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸
Wilshire Oncology Medical Group, Incorporated - Pomona, Pomona, California, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy